FR-235222
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Enzyme inhibitors |
| Catalog number | BBF-03556 |
| CAS | |
| Molecular Weight | 556.69 |
| Molecular Formula | C30H44N4O6 |
Online Inquiry
Description
FR-235222 is an immunosuppressive substance that inhibits mammalian histone deacetylase (HDAC). It is produced by the strain of Acremonium sp. No. 27082.
Specification
| Synonyms | FR 235222; FR235222 |
| IUPAC Name | (3S,6S,9S,12R,14S)-3-benzyl-6-ethyl-9-[(7R)-7-hydroxy-6-oxooctyl]-6,14-dimethyl-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone |
| Canonical SMILES | CCC1(C(=O)NC(C(=O)N2CC(CC2C(=O)NC(C(=O)N1)CCCCCC(=O)C(C)O)C)CC3=CC=CC=C3)C |
| InChI | InChI=1S/C30H44N4O6/c1-5-30(4)29(40)32-23(17-21-12-8-6-9-13-21)28(39)34-18-19(2)16-24(34)27(38)31-22(26(37)33-30)14-10-7-11-15-25(36)20(3)35/h6,8-9,12-13,19-20,22-24,35H,5,7,10-11,14-18H2,1-4H3,(H,31,38)(H,32,40)(H,33,37)/t19-,20+,22-,23-,24+,30-/m0/s1 |
| InChI Key | NJEYLEUCEPGDMG-PBYHWFFKSA-N |
Properties
| Appearance | White Waxy Substance |
| Boiling Point | 856.7±65.0°C at 760 mmHg |
| Melting Point | 225-230°C |
| Density | 1.2±0.1 g/cm3 |
Reference Reading
1. Dynamic methylation of histone H3K18 in differentiating Theileria parasites
Kevin Cheeseman, Guillaume Jannot, Nelly Lourenço, Marie Villares, Jérémy Berthelet, Teresa Calegari-Silva, Juliette Hamroune, Franck Letourneur, Fernando Rodrigues-Lima, Jonathan B Weitzman Nat Commun. 2021 May 28;12(1):3221. doi: 10.1038/s41467-021-23477-2.
Lysine methylation on histone tails impacts genome regulation and cell fate determination in many developmental processes. Apicomplexa intracellular parasites cause major diseases and they have developed complex life cycles with fine-tuned differentiation events. Yet, apicomplexa genomes have few transcription factors and little is known about their epigenetic control systems. Tick-borne Theileria apicomplexa species have relatively small, compact genomes and a remarkable ability to transform leucocytes in their bovine hosts. Here we report enriched H3 lysine 18 monomethylation (H3K18me1) on the gene bodies of repressed genes in Theileria macroschizonts. Differentiation to merozoites (merogony) leads to decreased H3K18me1 in parasite nuclei. Pharmacological manipulation of H3K18 acetylation or methylation impacted parasite differentiation and expression of stage-specific genes. Finally, we identify a parasite SET-domain methyltransferase (TaSETup1) that can methylate H3K18 and represses gene expression. Thus, H3K18me1 emerges as an important epigenetic mark which controls gene expression and stage differentiation in Theileria parasites.
2. Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review
Mahbobeh Montazeri, Saeed Mehrzadi, Mehdi Sharif, Shahabeddin Sarvi, Shayesteh Shahdin, Ahmad Daryani Parasitol Res. 2018 Oct;117(10):3045-3057. doi: 10.1007/s00436-018-6027-z. Epub 2018 Aug 8.
Currently, there is no approved therapy that can eradicate Toxoplasma gondii tissue cysts, which are responsible for chronic infection. This systematic review was performed to assess drugs or compounds that can be used as anti-T. gondii tissue cysts in vitro and in vivo. English electronic databases (i.e., PubMed, Science Direct, Scopus, Google Scholar, and Web of Science) were systematically searched for articles published up to 2017. A total of 55 papers published from 1987 to 2017 were eligible for inclusion in this systematic review. Among the drugs, atovaquone and azithromycin were found effective after long-term inoculation into mice; however, clinical cases of resistance to these drugs have been reported. Also, FR235222, QUI-11, tanshinone IIA, and hydroxyzine were shown to be effective against Toxoplasma cysts, but their effectiveness in vivo remains unknown. Additionally, compound 32, endochin-like quinolones, miltefosine, and guanabenz can be used as effective antiparasitic with the unique ability to reduce brain tissue cysts in chronically infected mice. Importantly, these antimicrobial agents are significant criteria for drug candidates. Future studies should focus on the biology and drug susceptibility of the cyst form of T. gondii in chronic toxoplasmosis patients to find more effective strategies that have sterilizing activity for eliminating T. gondii tissue cysts from the host, preventing disease relapse and potentially shortening the required duration of drug administration.
3. Benzodiazepine Scaffold as Drug-like Molecular Simplification of FR235222: A Chemical Tool for Exploring HDAC Inhibition
Rosario Randino, Ilaria Moronese, Elena Cini, Valentina Bizzarro, Marco Persico, Manuela Grimaldi, Mario Scrima, Anna Maria D'Ursi, Ettore Novellino, Eduardo Sobarzo-Sanchez, Luca Rastrelli, Caterina Fattorusso, Antonello Petrella, Manuela Rodriquez, Maurizio Taddei Curr Top Med Chem. 2017;17(4):441-459. doi: 10.2174/1568026616666160824105645.
Background: Synthesis, computational study and biological evaluation of peptidomimetic analogues of FR235222 (3), a natural immunosuppressant and HDAC inhibitor, have been reported. These new compounds, bearing α-hydroxyketone moiety, as more stable zinc binding group (ZBG), were evaluated in vitro as HDAC inhibitors against the human HDACs isoforms 1-9 and in cellular antiproliferative assays on U937 human leukemia cell line. The 1,4-benzodiazepin-2,5-dione (BDZ), capping group and the natural ZBG, (S,R)-2-amino-9-hydroxy-8-oxodecanoic acid (Ahoda), were evaluated in order to probe HDAC inhibition and/or paralogue selectivity. Some of the new derivatives showed an interesting activity against a number of HDAC isozymes. The observed activity profile was rationalized by a computational assisted SAR study, in order to understand how the BDZ classes interact with the enzyme into the catalytic pocket. Despite its poor solubility, compound 17b showed significant antiproliferative profile and HDAC inhibition activity. Result: In order to assess how the solubility issue could have affected the biological outcome, bioassay conditions were reproduced and quantification of precipitated particulate material was evaluated by turbidimetric and NMR studies together with physicochemical descriptors prediction. Thus, BDZ 17b has been chosen to be promising lead compounds for further optimization, in order to elucidate molecule- enzyme surface recognition.
Recommended Products
| BBF-02614 | Nystatin | Inquiry |
| BBF-01825 | Loganin | Inquiry |
| BBF-03754 | Castanospermine | Inquiry |
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-00677 | 3-Amino-3-deoxy-D-glucose | Inquiry |
| BBF-05862 | Epirubicin | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
